MINNEAPOLIS -- The small-molecule drug candidate danicamtiv showed promise for activating myosin in gene-related dilated cardiomyopathy (DCM), based on a small phase IIa study. Suggesting boosted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results